Forget Vertex Pharmaceuticals -- CRISPR Therapeutics is a better buy right now.

Crispr’s ability to cut genetic code like scissors has just started to turn into medicines. Now, gene editing pioneer ...

CRISPR Therapeutics (NasdaqGM:CRSP) reports significant progress in the commercial rollout of Casgevy, its approved gene editing therapy for sickle cell disease. Patient initiations for Casgevy have ...

DENVER, Jan. 28, 2026 (GLOBE NEWSWIRE) -- CRISPR gene-editing, and related genome engineering technologies, are reshaping industries from medicine to materials, with breakthroughs in treating genetic ...

With a shared purpose, we can realize the true promise of CRISPR and improve healthcare, providing hope to more patients with ultra-rare genetic disorders.

Add Yahoo as a preferred source to see more of our stories on Google. Stanford researchers have developed CRISPR-GPT, an AI-powered copilot that guides gene-editing experiments. (CREDIT: Shutterstock) ...

Gene editing has moved from theory to bedside with a speed that would have seemed impossible a decade ago. A new wave of CRISPR advances is not only correcting single mutations in the lab but ...

Crispr stock yo-yoed while Intellia stock surged, on promising updates for their gene-editing efforts in cholesterol treatment and a swelling disorder. At the American Heart Association conference in ...

Related Stories CRISPR gene editing breakthrough eliminates 50% of head, neck tumors CRISPR transforms ordinary fat cells into cancer killing machines Labeling cells with barcodes: New CRISPR ...

Gene-editing techniques such as CRISPR-Cas9 have many uses in the area of food and agriculture. They can combat persistent drought and disease, and improve the colour and nutritional content of food ...

If you are wondering whether CRISPR Therapeutics at around US$53.52 is offering good value today, you are not alone. The stock often attracts investors who care about price versus potential. The share ...